At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Sovaprevir +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Trial to Evaluate the Safety, Tolerability, and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection
In Brief
A Phase 2 clinical trial evaluating Sovaprevir, ACH-3102, and 2 other interventions for Hepatitis C, Chronic. Completed, enrolled 30 participants.
Detailed Summary
The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with sovaprevir, ACH-0143102, and ribavirin (RBV) in genotype-1 (GT-1), treatment-naive, hepatitis C virus (HCV) participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
Countries--
CollaboratorsAchillion, a wholly owned subsidiary of Alexion
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedMay 2013
Primary CompletionNov 2013
Study CompletionApr 2014
TodayJul 2026
First PostedMay 8, 2013
Enrollment StartApr 1, 2013
Primary CompletionNov 1, 2013
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.2 years ago
Interventions
Sovaprevirdrug
Nonstructural protein 3/4A protease inhibitor.
ACH-3102drug
Nonstructural protein 5A inhibitor.
Ribavirindrug
Placebodrug